KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. [electronic resource]
Producer: 20140306Description: 1190-5 p. digitalISSN:- 1556-1380
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cisplatin -- administration & dosage
- Docetaxel
- Female
- Follow-Up Studies
- Glutamates -- administration & dosage
- Guanine -- administration & dosage
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation -- genetics
- Neoplasm Staging
- Pemetrexed
- Prognosis
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Retrospective Studies
- Survival Rate
- Taxoids -- administration & dosage
- Vinblastine -- administration & dosage
- Vinorelbine
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.